Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the potential for combining PROTACs with other therapeutic modalities in drug discovery and reports no clinical results.

This review discusses the development and clinical progression of PROTAC technology for targeted protein degradation, highlighting its potential to address previously "undruggable" targets but reports no new clinical results.

This review highlights the potential of PROTACs to transform cancer treatment by selectively degrading oncogenic proteins, overcoming drug resistance, and reducing toxicity; it also discusses challenges in optimizing these therapies for personalized applications.

This review outlines advances in topical PROTACs for localized protein degradation, focusing on AH-001 and GT20029 for skin conditions, but presents no new clinical trial results.

This review discusses the evolution of Cereblon ligands in PROTAC technology, highlighting chemical innovations that may enhance drug-likeness and applicability in protein degradation, while noting challenges and future research directions.

This study developed dissolving microneedles incorporating a new AR degrader for treating androgenetic alopecia, showing that a single application leads to superior hair regeneration compared to daily minoxidil, without systemic toxicity or androgen-related issues.

This study developed a method for designing peptide-based PROTAC drugs using advanced AI models, successfully identifying peptides that bind to specific receptors and incorporating them into a potential transdermal treatment for androgenetic alopecia.

This review discusses how recent advancements in computational and lab-based methods have enhanced peptide drug discovery, noting the efficiency and cost benefits over traditional approaches and the potential for targeting difficult protein interactions, including protein degradation using proteolysis-targeting chimeras.

This review highlights how integrating medicinal chemistry with delivery science could transform the limitations of PROTACs—such as poor solubility and low cell permeability—into strengths, potentially advancing these compounds from experimental stages to clinical applications by optimizing their delivery and enhancing therapeutic efficacy.

This article discusses the impact of PROTACs technology in transforming drug discovery with its novel degradation mechanism, but it reports no new experimental findings.

This review detailed the significant progress and challenges in the design and application of PROTACs, a novel class of cancer therapeutics, highlighting their clinical trials, design complexities, and the role of artificial intelligence in improving their efficacy and selectivity for cancer therapy.

This review highlights the potential of PROTAC technology in drug discovery for previously undruggable targets, particularly in cancer therapy, while emphasizing the urgent need to discover more E3 ligase recruiters to optimize targeted protein degradation.

This review examines the development and challenges of using PROTACs, a targeted protein degradation strategy, to treat cancer by degrading specific proteins like PARPs and GPX4, highlighting issues such as target diversification and bioavailability.

This review discusses the progress and challenges of targeted protein degradation therapies, highlighting the increasing number of degraders in cancer clinical trials and the limited diversity in targeted proteins, primarily focusing on those employing CRL4^CRBN as the E3 ligase.

This study demonstrated that de novo designed bifunctional proteins can target and degrade BCL-xL, leading to cell apoptosis, suggesting a new approach to targeted protein degradation therapy.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

This review discusses how targeting protein degradation processes may help overcome cancer drug resistance, but reports no new clinical results and suggests further research for precise therapeutic strategies.

This study found that Malt1, particularly its protease activity, plays a crucial role in maintaining Treg cell function and homeostasis, with its inactivation leading to autoimmune diseases and altered immune responses in mice.

This study observed that in aged mouse skin, there was an increase in IL-17-expressing T helper cells, γδ T cells, and innate lymphoid cells, and blocking IL-17 signaling reduced skin inflammation and delayed age-related changes, suggesting it as a potential target to mitigate skin aging.

This study found that matriptase, a membrane serine protease, is crucial for maintaining multiple types of epithelial tissues in mice, with its absence leading to severe organ dysfunction and increased permeability.

This study found that in Arabidopsis seedlings, tonoplast intrinsic proteins are targeted to the vacuole via at least two pathways, including pathways with differing sensitivity to a chemical inhibitor that affect root hair growth and PIN2 targeting.

This review found that among emerging technologies for skin anti-aging, stem cell therapies using recipient chimerism might be more beneficial than CRISPR-Cas9 and other current innovations, though further studies on safety and efficacy are needed.

This review examines integrins as pharmacological targets, discussing current integrin-based therapies and emphasizing the need to understand integrin mechanisms for successful drug development, without reporting new clinical results.

Male hormones affect COVID-19 severity and certain drugs targeting these hormones could help reduce the risk.

In this study, researchers developed de novo designed hetero-bifunctional proteins as an alternative approach for targeted protein degradation, successfully targeting BCL-xL for degradation in cells and inducing apoptosis, which may expand the range of addressable E3 ligases and disease targets.

This review discusses AR-modulating agents developed between 2012 and 2018, highlighting challenges with ligand-binding domain antagonists and proposing nonconventional approaches targeting other domains as promising strategies.

This review explores the role of Eph receptors and ephrins in skin cell processes, discussing their potential for therapeutic targeting in dermatological disorders, but it presents no new research findings.

In this review, researchers explored the multifaceted role of NF-κB signaling in various biological processes and diseases, including its interactions with other pathways, and discussed possible therapeutic approaches targeting this pathway for treating conditions like cancer, autoimmune disorders, and COVID-19.

This study introduced Cadd4, a peptide-based degrader developed using computer-aided drug design, which effectively reduced PCSK9 levels and increased LDL receptor expression, resulting in decreased plasma cholesterol and LDL-C levels in hypercholesterolemic mice, without liver toxicity.

This review discusses the pathogenesis of common sebaceous gland diseases and their molecular pathways, but it reports no new clinical findings.